Sanofi $2.2 billion vaccine deal comes alongside FDA setback

Sanofi agreed to buy Dynavax Technologies Corp. for about $2.2 billion, as it seeks to expand a vaccines business currently ...

Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline

Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline Paris, December 24, 2025.

Sanofi Makes $2.2 Billion Bet On Adult Vaccines With Dynavax Buy

Sanofi (SNY) to acquire Dynavax Technologies (DVAX) for $15.50 per share in cash, expanding its presence in adult ...

Sanofi multiple sclerosis therapy rejected by the FDA

Sanofi (SNY) stock is in focus as the company agrees to acquire Dynavax Technologies (DVAX) and the FDA rejects its multiple ...
pharmaphorum

Sanofi gets double blow for MS drug tolebrutinib

Tolebrutinib was one of three oral BTK inhibitors that Sanofi acquired as part of its $3.7 billion buyout of Principia ...

Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline

Dynavax's adult hepatitis B vaccine HEPLISAV-B is currently marketed in the US and is differentiated by its two-dose regimen over one month, which enables high levels of seroprotection faster than ...

This biotech stock soars 39%. Sanofi is buying it for $2.2 billion.

Shares of Meta Platforms (NASDAQ: META) have advanced 13% year to date, bringing its market value to $1.6 trillion. Meanwhile ...
PharmExec

JP Morgan 2026 Preview: Sanofi Looks to Bolster Future Pipeline

Sanofi has announced that Paul Hudson, CEO, will be in attendance at the 44 th annual JP Morgan Healthcare Conference in San ...